A Novel Long-Range Deletion Spanning CDC73 and Upper-Stream Genes Discovered in a Kindred of Familial Primary Hyperparathyroidism

Yi Yang

Peking Union Medical College Hospital Department of Endocrinology <https://orcid.org/0000-0003-4563-371X>

An Song

Peking Union Medical College Hospital

Min Nie

Peking Union Medical College Hospital

Yan Jiang

Peking Union Medical College Hospital

Mei Li

Peking Union Medical College Hospital Department of Endocrinology

Weibo Xia

Peking Union Medical College Hospital Department of Endocrinology

Xiaoping Xing

Peking Union Medical College Hospital Department of Endocrinology

Ou Wang (✉ wang_ou2010@126.com)

Peking Union Medical College Hospital Department of Endocrinology

Ya Hu

Peking Union Medical College Hospital Department of General Surgery

---

Research Article

Keywords: parathyroid carcinoma, familial hyperparathyroidism, CDC73, parafibromin, long-range deletion

Posted Date: June 11th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-591640/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Endocrine on November 2nd, 2021. See the published version at <https://doi.org/10.1007/s12020-021-02917-5>.

Abstract

Purpose

To confirm the exact break-point of a novel long-range deletion discovered in one female parathyroid carcinoma (PC) patient who has a strong family history suggesting familial hyperparathyroidism, and to investigate the expression of parafibromin in the patient's affected lesion.

Methods

Clinical information of one female patient as well as five of her relatives were collected. Their genomic DNA extracted from peripheral blood went through Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA). After completing whole genome sequencing (WGS), clone sequencing was also performed, whose result was aligned with standard human genome database after Sanger sequencing.

Results

The medical history of recurrent hypercalcemia after parathyroidectomy and histopathological investigation confirmed that the female patient with the diagnosis of PC. WGS displayed a novel 130kb long-range deletion spanning *UCHL5* to *CDC73* which was later confirmed by clone sequencing. MLPA showed similar results in four of her five relatives, suggesting these people to be carriers of the same long-range deletion, and three among them had a history of primary hyperparathyroidism (PHPT) ahead of the proband's first visit.

Conclusion

We discovered a novel 130kb long-range deletion spanning *CDC73* in a family of five-person, and the existence of the deletion was related to PHPT and PC. Our discovery validated the role of *CDC73* mutation in the occurrence of PHPT and PC, which provided new information to the genetic studies of PC.

1. Introduction

Primary hyperparathyroidism (PHPT), as the third most frequent endocrine disorder in western countries, is a metabolic bone disease caused by autonomous excessive parathyroid hormone (PTH). Parathyroid carcinoma (PC) is a rare pathologic type which comprises 0.5%–5% of patients with PHPT[1][2][3]. Since there are no specific clinical, biochemical, or radiological characteristics of PC, it has been a challenge for clinicians to distinguish PC from parathyroid adenoma (PA) or parathyroid hyperplasia (PH). Therefore, the diagnosis of PC is often made after surgery based on histopathological examinations, and sometimes after recurrence or metastasis.

PC is commonly sporadic, but it can also be a part of specific syndromes in familial PHPT including multiple endocrine neoplasia type 1 (MEN1) and 2A (MEN2A)[4], particularly, the hyperparathyroidism-jaw tumor syndrome (HPT-JT)[5][6]. Germline mutations of the *CDC73* (located in 1q32.1, initially named *HRPT2*) gene was initially associated with HPT-JT[7][6]. Till now, in 15%–70% of sporadic PC cases, *CDC73* mutations were found to be somatic, and in one-third of them, such mutations are found as germline[8].

The transcription product of tumor suppressor gene *CDC73* is a 531-amino acid protein parafibromin, which is responsible for cell cycle arrest by acting through both transcriptional and post-transcriptional control pathways[9]. Parafibromin has been proved to play a role in Wnt signaling pathway[10] and interact with polymerase β -associated factor 1 (PAF1) transcription elongation complex[11]². Its expression is detectable in PH and PA tissues through immunohistochemical methods, while PCs, it is missing, indicating that loss of parafibromin expression is a marker of parathyroid carcinoma.

Loss-of-function mutations of *CDC73* associated with PC result in loss of expression of parafibromin[12], abnormal parafibromin subcellular localization[13], or depleted anti-proliferative ability[14]. Till now, about 100 cases of *CDC73* germline loss-of-function mutation have been reported, most of which involve frameshift mutation or nonsense mutation[15]. Intragenic mutation or deletion of *CDC73* have also been discovered in a few cases of PC and related syndromes [16][17][18][19].

In this study, we reported the clinical feature of a PC patient who had a family history of PHPT and the genetic inspections of the patient's family of 7 people covering 3 generations. The clinical data and novel genetic findings of the long-range deletion spanning part of *CDC73* and several upstream genes will be of help in further understanding of the disease.

2. Subjects And Methods

The patient was diagnosed and monitored at the Department of Endocrinology, Peking Union Medical College Hospital (PUMCH) voluntarily. The Ethics Committee of PUMCH approved this study protocol. Collection of peripheral blood and genetic analysis were performed after acquiring the patient and her family's full consent.

Diagnosis of PHPT was established based on serum calcium (SCa) or albumin-corrected calcium (CCa, $CCa = SCa + [0.02 \times (40 - \text{albumin})]$) levels greater than 2.70 mmol/L and/or plasma ionized calcium (iCa) higher than 1.28 mmol/L, combining with elevated serum PTH levels in the absence of other causes of hypercalcemia[20]. Familial or syndromic PHPT such as MEN1, MEN2A, and HPT-JT were screened by full personal and family history with laboratory and imaging evaluation of relative endocrine glands, urinary system and jaws[21][22].

2.1 Clinical data

The clinical data were retrospectively collected from medical records maintained at PUMCH, including general characteristics, clinical manifestations (e.g., bone involvement, urinary system damage, gastrointestinal symptoms, and hypercalcemia crisis), treatment strategies, pathological features, and follow-up (postoperative recurrence and metastasis).

Serum and urinary biochemical markers were measured at the Department of Clinical Laboratory of PUMCH described previously[23]. Serum PTH was measured via chemiluminescence (Siemens ADVIA Centaur, Erlangen, Germany) with the normal range of 12-68 pg/mL. Serum 25-dihydroxy vitamin D was measured by electrochemiluminescence immunoassay (Roche Cobas E601, Germany). Histopathological classification of parathyroid lesions was determined by the pathologists at the Department of Pathology, PUMCH. Diagnostic criteria for parathyroid carcinoma including lesion's vascular invasion, perineural-space invasion, capsular penetration, and/or documented metastases[24]. Parafibromin immunohistochemistry (IHC) staining of parathyroid tissue collected through parathyroidectomy of the proband and the proband's brother was conducted as previously described[25] with a PA tissue from a previous study as a positive control.

2.2 Genetic analysis

Genomic DNA was extracted from peripheral blood leukocytes using a commercial kit (Blood DNA Midi Kit D3494, Omega Bio-Tek, Georgia, USA) following instructions given by the manufacturer. Sanger sequencing and results' analyzing of exons and splice regions of *CDC73* and *MEN1* of the proband were performed as previously described[26].

Copy number analysis was conducted by multiplex ligation-dependent probe amplification (MLPA) using the P466-A1 kit (MRC-Holland, Amsterdam, Netherlands) following manufacturers' protocol. Results of the MLPA products were obtained and analyzed on an ABI3130XL genetic analyzer (Applied Biosystems) using GeneMapper software (Applied Biosystems). Analysis of MLPA results was conducted with Coffalyser. Net software (Version 04, MRC-Holland, Amsterdam, The Netherlands) by comparing the sample's peak height of each electrophoresis fragment with those of the same length of standard comparisons. A ratio of 0.7-1.3 would be considered a normal copy number of the locus, while a ratio below 0.7 would be defined as half reduced copy number and a ratio above 1.3 would be defined as an increased copy number of the locus.

Approximately 1 ng of the patient's genomic DNA sample was sent to WuXiAppTec to perform whole genome sequencing (WGS). According to the manufacturer's instructions, Agilent liquid capture system (Agilent SureSelect Human All Exon V6) was used to enrich the exome sequence from the sample DNA. The qualified genomic DNA sample was randomly fragmented using a Covaris S220 sonicator into an average size of 180-280 bp. After connecting adaptors to both ends of the resulting fragments by paired ends (Illumina), they are selectively enriched in the PCR reaction. The extracted DNA was amplified using ligation-mediated PCR (LM-PCR), AMPureXP system (Beckman Coulter, Beverly, California, USA), and quantified using Agilent high sensitivity DNA assay on Agilent Bioanalyzer 2100 system. Finally, the DNA library was sequenced on Illumina for paired-end 150 bp reads.

After receiving the WGS results, primers PC-F and PC-R were designed flanking the deleted sequence using Oligo7 software (Version 7.60, Molecular Biology Insights Inc), after which PCR was done as described previously[26]. The product was sent to SinoGenoMax for Sanger sequencing and clone sequencing (ABI3130XL genetic analyzer, Applied Biosystems). Results of clone sequencing were analyzed by 4Peaks (Version 1.4, Neocleobites) and Basic Local Alignment Search Tool supported by Genomic Institute of the University of California, Santa Cruz.

3. Results

3.1 Case presentation

In 2013, a 33-year-old woman presented with bilateral lower limb weakness, light lower limb pain worsening with activity. She underwent examinations in a local hospital with the results of PTH 981 pg/ml, serum albumin corrected Ca 2.80 mmol/L (reference range: 2.08-2.60 mmol/L), P 0.67 mmol/L, Mg 0.4 mmol/L, alkaline phosphatase (ALP) 536 U/L. X-ray indicated the right mid-femur fracture and osteitis fibrosa cystica in the right lib. The right inferior parathyroid gland was resected, as the preoperative ultrasound indicated abnormal hyperplasia (4.5×3.5×3.0 cm). The pathological examination showed atypical parathyroid adenoma (APA) with Ki-67 of 10%. Her postoperative SCa and PTH levels reverted to normal ranges since the first day after surgery. At the 3-month follow-up, serum PTH was 258 pg/ml, SCa was 1.84 mmol/L. The patient did not follow up regularly.

In 2019, she came to our center for recurrent bilateral lower limb weakness with xerostomia. Physical examination revealed an old surgical scar on the neck with unremarkable cervical palpation and stable vital signs. Biochemical evaluation confirmed the recurrence of primary hyperparathyroidism: serum albumin corrected Ca 2.67 mmol/L (reference range: 2.13-2.70mmol/L), serum P 0.31 mmol/L (reference range: 0.81-1.45 mmol/L), PTH 752.8 pg/ml, plasma ionized Ca 1.56 mmol/L (reference range: 1.08-1.28 mmol/L), ALP 191 U/L, β -CTX 0.323 ng/ml, 24hUCa 4.3 mmol, 24hUP 11.96 mmol, 25OHD 11.5 ng/ml, 1,25[OH]₂D₃ 87.37 pg/ml. Both neck ultrasound and the parathyroid 99mTc-sestamibi scanning identified bilateral lesions. Bilateral renal calculi were detected by abdominal ultrasound. The BMD, as measured by DXA, was 0.981 g/cm² in the lumbar spines 1-4 (Z score 1.6), 0.880 g/cm² in the femur neck (Z score 0.5), and 0.799 g/cm² in the total hip (Z score 1.5). Serum calcitonin, insulin, proinsulin, and gastrin were all within normal ranges, and there were no abnormalities found in pituitary MRI and pancreatic enhanced MRI. The patient, accordingly,

underwent right superior and total left parathyroidectomy + total hemithyroidectomy + resection of surrounding anterior muscle of neck + neck lymphadenectomy. Pathological examinations confirmed the diagnosis of parathyroid carcinoma, with lesions infiltrating into thyroid tissue, surrounding muscle tissue and right recurrent laryngeal nerve (Figure1, A and B). Immunochemical examinations showed parafibromin ( ) (Figure1, D), PTH (+), CgA(+), Calcitonin( ), AE1/AE3(+), Syn(+), TTF-1( ), and Ki-67 index of 20%. Her serum levels of PTH (8.7 pg/ml) and calcium (2.01 mmol/L) significantly decreased postoperatively. She felt some numbness in her limbs without tetany and was treated with calcium carbonate (1.5 g/day) and calcitriol (1 μ g/day) which relieved her symptoms gradually. In 2020, after a year of surgery, her SCa level increased to 2.76 mmol/L, while the PTH level was 208 pg/mL. Both the

parathyroid 99mTc-sestamibi scanning and ultrasound identified no new lesion, so the patient chose to use cinacalcet instead of surgery. Three months after starting the medication, the patient experienced only occasional nausea. Her SCa level was 2.42 mmol/L at the time of the latest follow-up, while the PTH level ranged between 260-400 pg/mL.

The proband (III2) had a family history of PHPT and renal calculi (results of MLPA confirmed five of the family members, II3, II4, III3, IV1 and IV2, carried the same variation of *CDC73* gene) (Table 2 and Figure 2, A). II4 (patient's father) was diagnosed as PHPT at 36 years old and underwent a single gland parathyroidectomy for PA. No signs of recurrence or metastasis were found on her father in the 20-year follow-up. II3 (sister of the proband's father) and III3 (proband's brother) were also diagnosed as PHPT with renal calculi. III3 underwent examinations in our hospital with the results of PTH 224 pg/ml, serum albumin corrected Ca 2.70 mmol/L, plasma ionized Ca 1.29 mmol/L; the preoperative ultrasound and sestamibi-(99m)Tc indicated two abnormal hyperplasia in the left parathyroid. III3 underwent left superior and inferior parathyroidectomy with the pathological diagnosis of parathyroid adenoma (Figure 1, E). Immunochemical examinations showed PTH (+), CgA(+), Calcitonin(-), AE1/AE3(+), Syn(+), TTF-1(-), and Ki-67 index of 1%. IHC staining showed that nuclear parafibromin expression was also absent in III3's parathyroid sample (Figure 1, F). IV1 (proband's daughter) and IV2 (son of proband's brother) showed no clinical manifestation of PHPT with normal serum Ca and PTH levels.

3.2 Genetic findings

Sanger sequencing showed no point mutations of *CDC73* or *MEN1* of the proband, while results of MLPA showed a half-reduced copy number variant of exon 1-6 of *CDC73* and upper-stream *TROVE2* exon 8, *GLRX2* exon 3. But copy number of *ABCA4* exon 15 was unaltered. This copy number variation had not been described previously. The same MLPA results were also presented in II4 (patient's father), II3 (sister of the proband's father), III3 (proband's brother), and IV1 (proband's daughter) (Table 2).

WGS revealed the long-range missing covered part of *UCHL5*, *TROVE2*, *GLRX2*, and part of *CDC73* in the proband, and further clone sequencing confirmed that the 130kb deletion spanned chr1:193009590-193139118 (Figure 2, B). Considering results of MLPA and tight kinship connection, we presumed that the II4, II3, III3 and IV1 carried the same long-range missing.

4. Discussion

In this study, we have discovered and located a novel 130kb long-range deletion ranging chr1:193009590-193139118 spanning *GLRX2* to exon 6 of *CDC73* by conducting several genetic analyses. Clinical features of the patient and her family history have also been described. To our knowledge, this is the largest long-range deletion involving *CDC73* related to familial PHPT among Chinese population and the second-largest discovered in Asia.

PHPT can present with the form of sporadic or inherited when the latter of which accounted for approximately 10% of all PHPT cases[27]. Among the syndrome-related genes, *CDC73* is the second most commonly mutated one. Different investigations have shown that both point mutations and large deletions of *CDC73* can be the underlying genetic basis of oncogenesis of familial PHPT. In a previous study conducted at our center, 22 patients from four FIHP/ HPT-JT families were recruited. Genetic analysis revealed 3 point mutations and one gross deletion (exon 4-6) of *CDC73*[16]. In a systematic review of 153 FIHP kindreds that receiving genetic testing, 15% carried mutations of *CDC73*[28]. Thirty-seven hereditary PHPT patients from 15 FIHP kindreds were enrolled in the review, and genetic analysis showed one *CDC73* germline mutation in three unrelated kindreds, though copy number variant of *CDC73* was not analyzed. A British cohort of 30 familial hyperparathyroidism patients revealed one *CDC73* point mutations among 30 familial hyperparathyroidism patients. MLPA was also conducted at the same time, though no copy number variant of *CDC73* was found[29].

Apart from point mutation revealed by gene screening, there have been 6 studies reporting different long-range deletions involving *CDC73* that resulted in familial PHPT, PC, or HPT-JT. Cascón et al reported a germline 547kb long-range deletion spanning *CDC73* and *TROVE2*, *GLRX2*, *B3GALT2*, and *UCHL5* found in a two-generation HPT-JT family, resulted in PHPT or ossifying jaw fibroma among 6 individuals of this family[17]. Bricarie et al discovered 20 patients bearing *CDC73* mutations from 250 patients diagnosed with PHPT, HPT-JT, FIHP, non-familial HPT, and PC[30]. Among these 20 patients, 7 unrelated patients carried a germinal gross deletion of *CDC73*. Four of the seven patients carried intragenic deletion, and three bore whole *CDC73* deletion, resulting in PA and PC respectively in these two *CDC73* differently affected groups. Another study also discovered similar deletion of exon 1-17 in one PC patient[31]. Mahajan reported a novel deletion of *CDC73* involving exon 1-13 in a recurrent PC patient[32]. Muscarella's investigation of one HPT-JT family of 9 people revealed a deletion of exon 1-10 of *CDC73* among 7 of them[33]. The same deletion of *CDC73* was also found in a FIHP family consisted of 7 deletion carriers[19], among which 6 people were previously diagnosed with PHPT and had gone through parathyroidectomy, revealing 2 PCs, 1 APA, and 3 PAs. Taking the results of *CDC73* screening among PHPT, PC, HPT-JT, FIHP and case reports on *CDC73* deletion together into consideration, we presume that though germline *CDC73* mutation is accountable for only part of PHPT, considering the high prevalence of PC, HPT-JT and FIHP among *CDC73* carriers, it is still necessary to perform *CDC73* deletion investigation on patients without *CDC73* point mutation but with PC or a family history of PHPT.

Aside from *CDC73*, some other genes were affected by the long-range deletion in our case. One of them is *UCHL5*, also known as *UCH37*, which is the coding gene of ubiquitin carboxyl-terminal hydrolase isozyme L5 (UCHL5, also named UCH37). UCHL5 is a member of the ubiquitin C-terminal hydrolases (UCHs) family, which is believed to disassemble Lys48-linked poly-ubiquitin from the distal subunit of the chain in cells selectively[34]. Over-expressed *UCHL5* has been observed in hepatocellular carcinoma[35], esophageal squamous cell carcinoma[36] and epithelial ovarian cancer[37] tissues, and it has been associated with poor clinical outcome. In vitro experiments have indicated the relationship between silenced *UCHL5* and reduced *PAI-1*[38] expression, which are believed to promote tumor migration and invasion through TGF- β dependent pathways. In our case, neither the patient nor her family members have shown clinical manifestations of diseases related to the lack of expression of *UCHL5*, suggesting that the expression of a single allele is sufficient for the normal functioning of the pathway.

The whole length of *TROVE2* is also affected in the long-range deletion. The 12-exon *TROVE2* is officially named *RO60*, and it encodes the protein RO60 which is ubiquitously expressed in brain, prostate and 25 other tissues. The highly conserved RO60 has a much common name, SSA2, the existence of which has been associated with autoimmune diseases (such as Sjögren syndrome[39] and systemic lupus erythematosus[40][41][42]). Previous studies have indicated the possible relationship between RO60 and poor clinical outcomes in breast cancer, melanoma, non-Hodgkin lymphoma, and T-cell lymphoma[43][44][45]. A recent research discovered the increased expression of RO60 in pancreatic ductal adenocarcinoma tissues while using siRNA to knockdown RO60 exerted decreased cell proliferation and invasion in vitro and repressed subcutaneous tumor growth in vivo[46]. To date, the downregulation of *TROVE2* has not been proved to be relevant with PC or any other diseases. The clinical manifestation of our case hasn't shown the trace of autoimmune diseases, prompting that the deletion of one *TROVE2* allele may not be a deciding influential factor.

Results of WGS showed that *GLRX2* was also involved in the affected area. *GLRX2* is also named *GRX2*, and the protein it encodes is a member of the glutaredoxin family of proteins that maintain cellular thiol homeostasis. GRX2 plays the role of mitochondrial redox homeostasis and cellular differentiation and transformation. Previous research has shown that over-expressed Grx2 protected the heart from doxorubicin and ischemia-induced cardiac injury in mice, while knocking-out Grx2 induces left ventricular hypertrophy and fibrosis[47]. Another research showed that zebrafish with silenced *Grx2* presented with loss of all types of neurons by apoptotic cell death and unable to develop axonal scaffold[48]. Though there hasn't been evidence concerning the downregulation of *GLRX2* and specific diseases in human, attention should be paid for the reason that GRX2 mediates thiol redox signaling who anti-apoptotic function of cell that involves tumorigenesis.

Some limitations of our study should be mentioned. First, there is still no clear evidence indicating whether *UCLH5*, *TROVE2* or *GLRX2* is related to parathyroid function or proliferation, which needs further clarifications. Second, all of the 5 persons detected by MLPA that carried a long-range deletion should be analyzed for structural variation, but in fact, only the proband received a WGS analysis. Furthermore, family member IV1 (eight-year-old) who was a carrier of the long-range deletion presented with normal serum calcium and PTH levels. Considering the association between familial PHPT/PC and inactivating mutation of *CDC73*, a close follow-up is essential for monitoring the onset of PHPT as early as possible.

Conclusion

We found a novel 130kb deletion spanning exon 1-6 of *CDC73* and the upper-stream *UCLH5*, *TROVE2* and *GLRX2* in 5 patients among a family of three generations. The clinical manifestations of the 5 deletion carriers were also described, confirming not only the association between inactivating mutation of *CDC73* and familial PHPT, but also the necessity of screening for long-range deletion of *CDC73* when no point mutation of *CDC73* was found in familial PHPT, especially PC patients. Genetic investigations and follow-up should also be performed in the proband's kindred if possible due to the malignancy of PC and the heritability of the underlying mutation. Our discovery expanded the genetic mutation spectrum of *CDC73* associated familial PHPT, suggesting genetic analysis may be of help for planning surgical extents and genetic counseling.

Declarations

Funding

This work was supported by the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine (CAMS- I2M) (No. 2017-I2M-1-001) and the National Natural Science Foundation of China (No. 82070817).

Conflict of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the reported research. All authors contributed to the article and approved the submitted version.

Availability of data and material Not applicable.

Code availability Not applicable.

Authors' contributions

All authors contributed to the article and approved the submitted version.

Yi Yang and An Song contributed equally and would be considered as co-first authors;

Ou Wang and Ya Hu are co-corresponding authors.

Ethics approval

This study was approved by the Ethics Committee of Peking Union Medical College Hospital and conducted under the instructions of the principles in the Declaration of Helsinki.

Consent to participate

Written informed consent to participate was obtained from all participants.

Consent for publication

Written informed consent for publication was obtained from all participants.

Acknowledgment We thank the patient and the family for permitting us to publish certain information.

References

1. N. Talat and K. M. Schulte, *Ann. Surg. Oncol.* **17**, 2156 (2010).
2. F. Cetani, E. Pardi, and C. Marcocci, *J. Endocrinol. Invest.* **39**, 595 (2016).
3. A. S. Salcuni, F. Cetani, V. Guarnieri, V. Nicastro, E. Romagnoli, D. de Martino, A. Scillitani, and D. E. C. Cole, *Best Pract. Res. Clin. Endocrinol. Metab.* **32**, 877 (2018).
4. P. J. Jenkins, M. A. Satta, M. Simmgen, W. M. Drake, C. Williamson, D. G. Lowe, K. Britton, S. L. Chew, R. V Thakker, and G. M. Besser, *Clin. Endocrinol. (Oxf)*. **47**, 747 (1997).
5. L. Cinque, F. Pugliese, A. S. Salcuni, A. Scillitani, and V. Guarnieri, *Best Pract. Res. Clin. Endocrinol. Metab.* **32**, 891 (2018).
6. A. J. Gill, *Endocr. Pathol.* **25**, 30 (2014).
7. J. D. Carpten, C. M. Robbins, A. Villablanca, L. Forsberg, S. Presciuttini, J. Bailey-Wilson, W. F. Simonds, E. M. Gillanders, A. M. Kennedy, J. D. Chen, S. K. Agarwal, R. Sood, M. P. Jones, T. Y. Moses, C. Haven, D. Petillo, P. D. Leotlela, B. Harding, D. Cameron, A. A. Pannett, A. Höög, H. 3rd Heath, L. A. James-Newton, B. Robinson, R. J. Zarbo, B. M. Cavaco, W. Wassif, N. D. Perrier, I. B. Rosen, U. Kristoffersson, P. D. Turnpenny, L.-O. Farnebo, G. M. Besser, C. E. Jackson, H. Morreau, J. M. Trent, R. V Thakker, S. J. Marx, B. T. Teh, C. Larsson, and M. R. Hobbs, *Nat. Genet.* **32**, 676 (2002).
8. T. M. Shattuck, S. Välimäki, T. Obara, R. D. Gaz, O. H. Clark, D. Shoback, M. E. Wierman, K. Tojo, C. M. Robbins, J. D. Carpten, L.-O. Farnebo, C. Larsson, and A. Arnold, *N. Engl. J. Med.* **349**, 1722 (2003).
9. G. E. Woodard, L. Lin, J.-H. Zhang, S. K. Agarwal, S. J. Marx, and W. F. Simonds, *Oncogene* **24**, 1272 (2005).
10. C. Mosimann, G. Hausmann, and K. Basler, *Cell* **125**, 327 (2006).
11. A. Yart, M. Gstaiger, C. Wirbelauer, M. Pecnik, D. Anastasiou, D. Hess, and W. Krek, *Mol. Cell. Biol.* **25**, 5052 (2005).
12. C. Juhlin, C. Larsson, T. Yakoleva, I. Leibiger, B. Leibiger, A. Alimov, G. Weber, A. Höög, and A. Villablanca, *Endocr. Relat. Cancer* **13**, 509 (2006).
13. L. Lin, M. Czapiga, L. Nini, J.-H. Zhang, and W. F. Simonds, *Mol. Cancer Res.* **5**, 183 (2007).
14. C. Zhang, D. Kong, M.-H. Tan, D. L. J. Pappas, P.-F. Wang, J. Chen, L. Farber, N. Zhang, H.-M. Koo, M. Weinreich, B. O. Williams, and B. T. Teh, *Biochem. Biophys. Res. Commun.* **350**, 17 (2006).
15. K. van der Tuin, C. M. J. Tops, M. A. Adank, J.-M. Cobben, N. A. T. Hamdy, M. C. Jongmans, F. H. Menko, B. P. M. van Nesselrooij, R. T. Netea-Maier, J. C. Oosterwijk, G. D. Valk, B. H. R. Wolffenbuttel, F. J. Hes, and H. Morreau, *J. Clin. Endocrinol. Metab.* **102**, 4534 (2017).
16. J. Kong, O. Wang, M. Nie, J. Shi, Y. Hu, Y. Jiang, M. Li, W. Xia, X. Meng, and X. Xing, *Clin. Endocrinol. (Oxf)*. **81**, 222 (2014).
17. A. Cascón, C. V. Huarte-Mendicoa, L. Javier Leandro-García, R. Letón, J. Suela, A. Santana, M. B. Costa, I. Comino-Méndez, I. Landa, L. Sánchez, C. Rodríguez-Antona, J. C. Cigudosa, and M. Robledo, *Genes. Chromosomes Cancer* **50**, 922 (2011).
18. A. Dutta, R. Pal, N. Jain, P. Dutta, A. Rai, A. Bhansali, A. Behera, U. N. Saikia, V. Vishwajeet, D. Collier, H. Boon, M. Korbonits, and S. K. Bhadada, *J. Endocr. Soc.* **3**, 2224 (2019).
19. E. Korpi-Hyövälti, T. Cranston, E. Ryhänen, J. Arola, K. Aittomäki, T. Sane, R. V. Thakker, and C. Schalin-Jäntti, *J. Clin. Endocrinol. Metab.* **99**, 3044 (2014).
20. S. M. Wilhelm, T. S. Wang, D. T. Ruan, J. A. Lee, S. L. Asa, Q. Y. Duh, G. M. Doherty, M. F. Herrera, J. L. Pasieka, N. D. Perrier, S. J. Silverberg, C. C. Solórzano, C. Sturgeon, M. E. Tublin, R. Udelsman, and S. E. Carty, *JAMA Surg.* **151**, 959 (2016).
21. J. Kong, O. Wang, M. Nie, J. Shi, Y. Hu, Y. Jiang, M. Li, W. Xia, X. Meng, and X. Xing, *PLoS One* **11**, (2016).
22. W. Wang, J. Kong, M. Nie, Y. Jiang, M. Li, W. Xia, X. Meng, X. Xing, and O. Wang, *Clin. Endocrinol. (Oxf)*. **87**, 865 (2017).
23. A. Song, Y. Yang, Y. Wang, S. Liu, M. Nie, Y. Jiang, M. Li, W. Xia, O. Wang, and X. Xing, *Endocr. Pract.* **26**, 1093 (2020).
24. L. D. Ritchie, E. B. Fung, B. P. Halloran, J. R. Turnlund, M. D. Van Loan, C. E. Cann, and J. C. King, *Am. J. Clin. Nutr.* **67**, 693 (1998).
25. O. Wang, C. Wang, M. Nie, Q. Cui, H. Guan, Y. Jiang, M. Li, W. Xia, X. Meng, and X. Xing, *PLoS One* **7**, (2012).

26. Y. Yang, X. Chu, M. Nie, A. Song, Y. Jiang, M. Li, W. Xia, X. Xing, and O. Wang, *Endocrine* **69**, 212 (2020).
27. W. D. Fraser, *Lancet* **374**, 145 (2009).
28. E. Pardi, S. Borsari, F. Saponaro, F. Bogazzi, C. Urbani, S. Mariotti, F. Pigliaru, C. Satta, F. Pani, G. Materazzi, P. Miccoli, L. Grantaliano, C. Marcocci, and F. Cetani, *PLoS One* **12**, 1 (2017).
29. S. Mariathasan, K. A. Andrews, E. Thompson, B. G. Challis, S. Wilcox, H. Pierce, J. Hale, S. Spiden, G. Fuller, H. L. Simpson, B. Fish, P. Jani, I. Seetho, R. Armstrong, L. Izatt, M. Joshi, A. Velusamy, S. M. Park, and R. T. Casey, *Clin. Endocrinol. (Oxf)*. **93**, 409 (2020).
30. L. Bricaire, M. F. Odou, C. Cardot-Bauters, B. Delemer, M. O. North, S. Salenave, D. Vezzosi, J. M. Kuhn, A. Murat, P. Caron, J. L. Sadoul, C. Silve, P. Chanson, A. Barlier, E. Clauser, N. Porchet, and L. Groussin, *J. Clin. Endocrinol. Metab.* **98**, 403 (2013).
31. P. S. A. Wijewickrama and N. P. Somasundaram, *Case Rep. Endocrinol.* **2020**, 0 (2020).
32. G. Mahajan and A. Sacerdote, *BMJ Case Rep.* **11**, (2018).
33. L. A. Muscarella, D. Turchetti, A. Fontana, F. Baorda, O. Palumbo, A. Ia Torre, D. de Martino, R. Franco, N. S. Losito, A. Repaci, U. Pagotto, L. Cinque, M. Copetti, M. G. Chiofalo, L. Pezzullo, P. Graziano, A. Scillitani, and V. Guarnieri, *Oncotarget* **9**, 20721 (2018).
34. Y. A. Lam, G. N. DeMartino, C. M. Pickart, and R. E. Cohen, *J. Biol. Chem.* **272**, 28438 (1997).
35. Y. Fang, D. Fu, W. Tang, Y. Cai, D. Ma, H. Wang, R. Xue, T. Liu, X. Huang, L. Dong, H. Wu, and X. Shen, *Biochim. Biophys. Acta - Mol. Cell Res.* **1833**, 559 (2013).
36. Y. Chen, D. Fu, J. Xi, Z. Ji, T. Liu, Y. Ma, Y. Zhao, L. Dong, Q. Wang, and X. Shen, *Dig. Dis. Sci.* **57**, 2310 (2012).
37. L. Wang, Y. J. Chen, K. Xu, Y. Y. Wang, X. Z. Shen, and R. Q. Tu, *Tumor Biol.* **35**, 11427 (2014).
38. A. J. Cutts, S. M. Soond, S. Powell, and A. Chantry, *Int. J. Biochem. Cell Biol.* **43**, 604 (2011).
39. M. A. Alspaugh and E. M. Tan, *J. Clin. Invest.* **55**, 1067 (1975).
40. R. L. Loch, B. B. Beaulieu Jr, E. J. T. Chrystal, and P. Goldman, *Science (80-.)*. **211**, 400 (1981).
41. S. L. Deutscher, J. B. Harley, and J. D. Keene, *Proc. Natl. Acad. Sci. U. S. A.* **85**, 9479 (1988).
42. E. Ben-Chetrit, B. J. Gandy, E. M. Tan, and K. F. Sullivan, *J. Clin. Invest.* **83**, 1284 (1989).
43. B. C. Böckle, G. Stanarevic, G. Ratzinger, and N. T. Sepp, *Br. J. Dermatol.* **167**, 1067 (2012).
44. S. Bernatsky, R. Ramsey-Goldman, J. Labrecque, L. Joseph, J. F. Boivin, M. Petri, A. Zoma, S. Manzi, M. B. Urowitz, D. Gladman, P. R. Fortin, E. Ginzler, E. Yelin, S. C. Bae, D. J. Wallace, S. Edworthy, S. Jacobsen, C. Gordon, M. A. Dooley, C. A. Peschken, J. G. Hanly, G. S. Alarcón, O. Nived, G. Ruiz-Irastorza, D. Isenberg, A. Rahman, T. Witte, C. Aranow, D. L. Kamen, K. Steinsson, A. Askanase, S. Barr, L. A. Criswell, G. Sturfelt, N. M. Patel, J. L. Senécal, M. Zummer, J. E. Pope, S. Ensworth, H. El-Gabalawy, T. McCarthy, L. Dreyer, J. Sibley, Y. St. Pierre, and A. E. Clarke, *J. Autoimmun.* **42**, 130 (2013).
45. J. G. Routsias, J. D. Goules, G. Charalampakis, S. Tzima, A. Papageorgiou, and M. Voulgarelis, *Semin. Arthritis Rheum.* **43**, 178 (2013).
46. D. Liu, W. Qian, D. Li, and L. Kong, *Biochem. Biophys. Res. Commun.* **495**, 2519 (2018).
47. R. J. Mailloux, J. Y. Xuan, S. McBride, W. Maharsy, S. Thorn, C. E. Holterman, C. R. J. Kennedy, P. Rippstein, R. DeKemp, J. Da Silva, M. Nemer, M. Lou, and M. E. Harper, *J. Biol. Chem.* **289**, 14812 (2014).
48. L. Bräutigam, L. D. Schütte, J. R. Godoy, T. Prozorovski, M. Gellert, G. Hauptmann, A. Holmgren, C. H. Lillig, and C. Berndt, *Proc. Natl. Acad. Sci. U. S. A.* **108**, 20532 (2011).

Tables

Table 1. Clinical manifestations and biochemical indices of the PHPT family

Family member	Age of diagnosis (year)	Skeletal involvement	Urinary involvement	Gastrointestinal symptoms	Hypercalcemic crisis	Serum Ca (mmol/L)	Serum P (mmol/L)	Serum ALP (U/L)	Serum PTH (pg/mL)
II4	36	yes	yes	no	no	2.86	0.76	219	289
II3	58	no	yes	no	no	2.42	0.86	112	124
III3	31	no	yes	no	no	2.54	0.86	355	251
IV1	6	no	no	no	no	2.47	1.73	354	23
IV2	7	no	no	no	no	2.46	1.78	427	53

Note: Normal reference ranges for indices:Ca (serum calcium): 2.13-2.70 mmol/L. P (serum phosphorous): 0.81-1.45 mmol/L. ALP (alkaline phosphatase): 30-120 U/L. PTH (serum parathyroid hormone): 13-65 pg/mL.

Table 2. Final copy number variation of *CDC73* and related genes detected by MLPA.

Family member	Copy number ratio												
	ABCA4-15	TROVE2-8	GLRX2-3	CDC73-1	CDC73-2	CDC73-3	CDC73-4	CDC73-5	CDC73-6	CDC73-7	CDC73-8	CDC73-9	CDC73-10
III2 (proband)	0.92	0.57	0.53	0.52	0.51	0.52	0.57	0.51	0.59	1	0.99	1	0.93
II4	0.87	0.5	0.54	0.5	0.52	0.47	0.57	0.51	0.58	1.01	0.99	0.93	0.93
II3	0.9	0.52	0.49	0.52	0.48	0.49	0.56	0.52	0.6	1.04	0.98	0.86	0.92
III3	0.92	0.51	0.49	0.48	0.5	0.47	0.54	0.5	0.54	0.98	0.93	0.95	0.96
IV1	0.9	0.5	0.47	0.47	0.49	0.48	0.54	0.5	0.6	1.01	0.94	0.96	0.89
IV2	0.89	0.95	0.95	1	0.92	1	1.06	1.05	1.09	0.97	0.99	0.97	0.95

Note: A ratio between 0.7-1.3 is considered a normal copy number of the locus. A ratio below 0.7 is defined as half reduced copy number, and a ratio above 1.3 is defined as an increased copy number of the locus.

Figures

Figure 1

Histological images and immunohistochemistry (IHC) staining of the proband and the proband's brother (II3). A: the image of the proband's affected parathyroid and adjacent tissue (10×, HE staining). Invasion of parathyroid into sternocleidomastoid muscle can be seen clearly. B: the image of hyperplastic tissue of affected parathyroid breaking through the capsule. C: the image of the proband's affected parathyroid tissue, (100×, HE staining). D: the image of parafibromin IHC of the proband, showing complete loss of expression of parafibromin. E: the image of the proband's brother(II3)'s affected parathyroid tissue, (100×, HE staining). F: the image of parafibromin IHC of the proband's brother(II3)'s, showing partial loss of expression of parafibromin. G: the image of HE staining of one parathyroid adenoma patient's affected parathyroid tissue (100×, HE staining). H: the image of parafibromin IHC of the PA patient's affected tissue, showing normal expression of parafibromin.

Figure 2

A: Pedigree chart of the patient. Black solid square/circle: person diagnosed with PHPT. Slash line filled square/circle: person carrying CDC73 mutation. Shaded square/circle: a person without CDC73 mutation. Crossed-out square/circle with single slash line: deceased member. B: Peak chart showing results of clone sequencing and respected model picture of an affected genomic region. (Illustrated by 4Peaks and Adobe Photoshop.)